Scrip - Pharma News And Expert Analysis For Commercial Decision Makers since 1972

Scrip Asia 100 ebook

Citeline's latest Scrip Asia 100 e-book is live! Visit the microsite to download the report.


Spotlight On Clinical Trials


Industry Successes Shine At The 20th Annual Scrip Awards

The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.

Focus On Asia


Data Analysis


R&D


Industry Successes Shine At The 20th Annual Scrip Awards

 
• By 

The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.

Atea Aims For Underserved HCV Niche With Combo Regimen

 
• By 

With high SVR rates and good safety/tolerability in Phase II, Atea hopes to take its antiviral combo into Phase III. It sees a need for hepatitis C regimens that boost therapeutic compliance.

Lilly’s Head-To-Head Trial Reaffirms Zepbound Efficacy Versus Wegovy

 

Zepbound led to greater weight loss versus Wegovy in a Phase III trial, bolstering its position as the superior product in the fast-growing obesity space.

Janux Has A License To Thrill With 007’s Prostate Cancer Results

 

The masked T-cell engager has produced eye-catching results in heavily pre-treated prostate cancer patients, and Janux is aiming to jump ahead of Novartis’s Pluvicto in treatment regimens.

Business


Industry Successes Shine At The 20th Annual Scrip Awards

 
• By 

The Scrip Awards has been celebrating industry successes for 20 years now and the 2024 ceremony at the beautiful Raffles London at the OWO saw Novo Nordisk and Bill Burns taking home the top prizes.

Health Care Industry Reels After UnitedHealthcare CEO Is Killed Outside NYC Hotel

 
• By 

The motive for the shocking murder of Brian Thompson in New York City was still unknown Wednesday afternoon.

Genentech Finds Another Nanoparticle Partner In COUR

 
• By 

Deal Snapshot: Genentech will pay $40m up front and in the near term, with milestone fees of up to $900m-plus, to use COUR’s tolerogenic nanoparticle treatments in an undisclosed autoimmune disease.

Coherus Continues Funding IO Ambitions By Offloading Biosimilars

 
• By 

Coherus agreed to sell its biosimilar of Amgen’s Neulasta to Intas in a deal that will clear significant near-term debt and provide funds for a label-expansion strategy for its PD-1 agent Loqtorzi.

Scrip Originals


Stock Watch: AHA Conference Disappointments

 
• By 

Presenting data or announcing a licensing transaction at an appropriately themed conference would normally be expected to be viewed favorably by investors. This is not always the case, however.

Finance Watch: PIPEs Still Key Even As FOPO Fundraising Climbs

 
• By 

Public Company Edition: Biomedtracker data show the amount of money raised in both PIPEs and follow-on offerings surging in 2024. Olema and Cidara raised $250m and $105m, respectively, in recent private placements, while Spyre and Replimune grossed $200m and $140m in FOPOs.

Pipeline Watch: Nine Approvals And Six Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Deal Watch: Sarepta Targets RNAi In Broad Collaboration With Arrowhead

 
• By 

Plus deals involving Novartis with Vyriad, Ratio and Schrödinger; Pharmanovia/Lindis, Pulmatrix/Cullgen, Entero/Journey, Roche/Flare and AlloVir/Kalaris.